<p><em>预计第四季度收入同比增长约 25%</em></p>
<p><em>预计 2025 年全年收入约为 3.8 亿美元</em></p>
<p>加利福尼亚州布里斯班 --（商业资讯）--CareDx, Inc.（纳斯达克：CDNA）——移植公司™，一家专注于为移植患者和护理人员发现、开发和商业化临床差异化、高价值医疗解决方案的领先精准医疗公司，今天报告了 2025 年第四季度和全年初步未经审计的财务结果。</p>
<p><strong>2025 年第四季度初步财务结果</strong></p>
<ul>
<li>收入约为 1.08 亿美元，同比增长 25%</li>
<li>检测服务收入约为 7800 万美元，同比增长 23%</li>
<li>检测服务量约为 53,000，同比增长 17%</li>
<li>每次检测的平均收入约为 1,470 美元，包括约 500 万美元的前期收入</li>
<li>患者和数字解决方案收入约为 1700 万美元，同比增长 47%</li>
<li>产品收入约为 1300 万美元，同比增长 17%</li>
<li>本季度回购 1200 万美元的股票，共 773,000 股，平均价格为每股 15.79 美元</li>
</ul>
<p><strong>2025 年全年初步财务结果</strong></p>
<ul>
<li>收入约为 3.8 亿美元，同比增长 14%</li>
<li>检测服务收入约为 2.74 亿美元，同比增长 10%</li>
<li>检测服务量约为 200,000，同比增长 14%</li>
<li>患者和数字解决方案收入约为 5700 万美元，同比增长 31%</li>
<li>产品收入约为 4800 万美元，同比增长 19%</li>
<li>截至 2025 年 12 月 31 日，现金、现金等价物和可交易证券约为 2 亿美元</li>
<li>本年度回购 8800 万美元的股票，共 580 万股，平均价格为每股 15.16 美元</li>
</ul>
<p>“我们在检测服务量增长和各业务板块创纪录收入方面又度过了一个强劲的季度，” 总裁兼首席执行官约翰·W·汉娜表示。“我们的解决方案销售策略正在奏效。2026 年，我们计划在这一商业势头的基础上，推进我们的 Transplant+ 创新管道。”</p>
<p>本新闻稿中呈现的初步财务信息基于 CareDx 当前的预期，可能会因完成常规年度审计程序等原因而进行调整。</p>
<p><strong>关于 CareDx – 移植公司</strong></p>
<p>CareDx 是一家精准医疗公司，致力于改善移植患者的结果并推动器官健康。公司的综合解决方案包括心脏、肾脏和肺移植的非侵入性分子检测；实验室产品；数字健康技术；以及支持移植前后护理的患者解决方案。CareDx 是移植患者基因组信息的领先提供者。有关更多信息，请访问 www.caredx.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含前瞻性声明，包括关于实现 CareDx 财务和运营目标的预期以及其对 2025 年的预期和展望。这些前瞻性声明基于目前可用的信息和 CareDx 当前的预期，仅在本声明日期有效，并且受到许多风险和不确定性的影响，这些风险和不确定性难以预测，且许多超出 CareDx 的控制范围，可能导致实际结果与预测结果存在重大差异，包括一般经济和市场因素，以及全球经济和市场的不确定性等，具体内容在 CareDx 向证券交易委员会（“SEC”）提交的文件中讨论，包括但不限于 CareDx 于 2025 年 2 月 28 日向 SEC 提交的截至 2024 年 12 月 31 日的财政年度的 10-K 表格年度报告，以及 CareDx 向 SEC 提交的其他报告。任何这些因素可能导致 CareDx 的实际结果、表现或成就与 CareDx 的前瞻性声明所预期或暗示的结果存在重大不利差异。请谨慎对待这些前瞻性声明。除法律要求外，CareDx 明确不承担更新或修订任何此类前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMTI3MTI2NzdyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMTI3MTI2NzdyMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20260112712677/en/</p>
<p><strong>CareDx, Inc.</strong></p>
<p>媒体</p>
<p>娜塔莎·莫希里安·瓦格纳</p>
<p><strong>nwagner@CareDx.com</strong></p>
<p><strong>投资者</strong></p>
<p>卡罗琳·科纳</p>
<p><strong>investor@CareDx.com</strong></p>
<p>来源：CareDx, Inc.</p>

CDNA

<p>CareDx, Inc. 宣布了 2025 年第四季度和全年初步财务结果，预计第四季度收入增长 25%，总计约为 1.08 亿美元，全年收入约为 3.8 亿美元，同比增长 14%。检测服务收入增长 10%，达到 2.74 亿美元，检测量增加 17%。公司还报告了第四季度回购股票 1200 万美元，全年回购 8800 万美元。首席执行官 John W. Hanna 强调了强劲的增长，并计划在 2026 年推进他们的创新管道</p>

<p><em>Expects Fourth Quarter Revenue Growth of Approximately 25% Year-Over-Year</em></p>
<div class="lb-trans"><p><em>预计第四季度收入同比增长约 25%</em></p>
</div><p><em>Expects Full Year 2025 Revenue of Approximately $380 Million</em></p>
<div class="lb-trans"><p><em>预计 2025 年全年收入约为 3.8 亿美元</em></p>
</div><p>BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today reported preliminary, unaudited financial results for the fourth quarter and full year 2025.</p>
<div class="lb-trans"><p>加利福尼亚州布里斯班 --（商业资讯）--CareDx, Inc.（纳斯达克：CDNA）——移植公司™，一家专注于为移植患者和护理人员发现、开发和商业化临床差异化、高价值医疗解决方案的领先精准医疗公司，今天报告了 2025 年第四季度和全年初步未经审计的财务结果。</p>
</div><p><strong>Preliminary Fourth Quarter 2025 Financial Results</strong></p>
<div class="lb-trans"><p><strong>2025 年第四季度初步财务结果</strong></p>
</div><ul>
<li>Revenue of approximately $108 million, an increase of 25% year-over-year</li>
<li>Testing services revenue of approximately $78 million, an increase of 23% year-over-year</li>
<li>Testing services volume of approximately 53,000, an increase of 17% year-over-year</li>
<li>Average revenue per test of approximately $1,470 including approximately $5 million in prior period revenue</li>
<li>Patient &amp; digital solutions revenue of approximately $17 million, an increase of 47% year-over-year</li>
<li>Product revenue of approximately $13 million, an increase of 17% year-over-year</li>
<li>Share repurchase of $12 million during the quarter for 773,000 shares at an average price of $15.79 per share</li>
</ul>
<div class="lb-trans"><ul>
<li>收入约为 1.08 亿美元，同比增长 25%</li>
<li>检测服务收入约为 7800 万美元，同比增长 23%</li>
<li>检测服务量约为 53,000，同比增长 17%</li>
<li>每次检测的平均收入约为 1,470 美元，包括约 500 万美元的前期收入</li>
<li>患者和数字解决方案收入约为 1700 万美元，同比增长 47%</li>
<li>产品收入约为 1300 万美元，同比增长 17%</li>
<li>本季度回购 1200 万美元的股票，共 773,000 股，平均价格为每股 15.79 美元</li>
</ul>
</div><p><strong>Preliminary Full Year 2025 Financial Results</strong></p>
<div class="lb-trans"><p><strong>2025 年全年初步财务结果</strong></p>
</div><ul>
<li>Revenue of approximately $380 million, an increase of 14% year-over-year</li>
<li>Testing services revenue of approximately $274 million, an increase of 10% year-over-year</li>
<li>Testing services volume of approximately 200,000, an increase of 14% year-over-year</li>
<li>Patient &amp; digital solutions revenue of approximately $57 million, an increase of 31% year-over-year</li>
<li>Product revenue of approximately $48 million, an increase of 19% year-over-year</li>
<li>Cash, cash equivalents and marketable securities of approximately $200 million as of December 31, 2025</li>
<li>Share repurchase of $88 million during the year for 5.8 million shares at an average price of $15.16 per share</li>
</ul>
<div class="lb-trans"><ul>
<li>收入约为 3.8 亿美元，同比增长 14%</li>
<li>检测服务收入约为 2.74 亿美元，同比增长 10%</li>
<li>检测服务量约为 200,000，同比增长 14%</li>
<li>患者和数字解决方案收入约为 5700 万美元，同比增长 31%</li>
<li>产品收入约为 4800 万美元，同比增长 19%</li>
<li>截至 2025 年 12 月 31 日，现金、现金等价物和可交易证券约为 2 亿美元</li>
<li>本年度回购 8800 万美元的股票，共 580 万股，平均价格为每股 15.16 美元</li>
</ul>
</div><p>“We had another quarter of strong testing services volume growth and record revenue across all segments of our business,” said John W. Hanna, President and CEO. “Our solutions selling strategy is working. In 2026, we plan to build on this commercial momentum and advance our Transplant+ innovation pipeline.”</p>
<div class="lb-trans"><p>“我们在检测服务量增长和各业务板块创纪录收入方面又度过了一个强劲的季度，” 总裁兼首席执行官约翰·W·汉娜表示。“我们的解决方案销售策略正在奏效。2026 年，我们计划在这一商业势头的基础上，推进我们的 Transplant+ 创新管道。”</p>
</div><p>The preliminary financial information presented in this press release is based on CareDx’s current expectations and may be adjusted as a result of, among other things, the completion of customary annual audit procedures.</p>
<div class="lb-trans"><p>本新闻稿中呈现的初步财务信息基于 CareDx 当前的预期，可能会因完成常规年度审计程序等原因而进行调整。</p>
</div><p><strong>About CareDx – The Transplant Company</strong></p>
<div class="lb-trans"><p><strong>关于 CareDx – 移植公司</strong></p>
</div><p>CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company’s integrated solutions include non‑invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics‑based information for transplant patients. For more information, please visit www.caredx.com.</p>
<div class="lb-trans"><p>CareDx 是一家精准医疗公司，致力于改善移植患者的结果并推动器官健康。公司的综合解决方案包括心脏、肾脏和肺移植的非侵入性分子检测；实验室产品；数字健康技术；以及支持移植前后护理的患者解决方案。CareDx 是移植患者基因组信息的领先提供者。有关更多信息，请访问 www.caredx.com。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release includes forward-looking statements, including expectations regarding the achievement of CareDx’s financial and operational goals and its expectations and prospects for 2025. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, all of which are difficult to predict and many of which are beyond CareDx’s control, that could cause the actual results to differ materially from those projected, including general economic and market factors, and global economic and marketplace uncertainties, among others discussed in CareDx’s filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明，包括关于实现 CareDx 财务和运营目标的预期以及其对 2025 年的预期和展望。这些前瞻性声明基于目前可用的信息和 CareDx 当前的预期，仅在本声明日期有效，并且受到许多风险和不确定性的影响，这些风险和不确定性难以预测，且许多超出 CareDx 的控制范围，可能导致实际结果与预测结果存在重大差异，包括一般经济和市场因素，以及全球经济和市场的不确定性等，具体内容在 CareDx 向证券交易委员会（“SEC”）提交的文件中讨论，包括但不限于 CareDx 于 2025 年 2 月 28 日向 SEC 提交的截至 2024 年 12 月 31 日的财政年度的 10-K 表格年度报告，以及 CareDx 向 SEC 提交的其他报告。任何这些因素可能导致 CareDx 的实际结果、表现或成就与 CareDx 的前瞻性声明所预期或暗示的结果存在重大不利差异。请谨慎对待这些前瞻性声明。除法律要求外，CareDx 明确不承担更新或修订任何此类前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMTI3MTI2NzdyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260112712677r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260112712677/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20260112712677/en/</p>
</div><p><strong>CareDx, Inc.</strong></p>
<div class="lb-trans"><p><strong>CareDx, Inc.</strong></p>
</div><p>Media</p>
<div class="lb-trans"><p>媒体</p>
</div><p>Natasha Moshirian Wagner</p>
<div class="lb-trans"><p>娜塔莎·莫希里安·瓦格纳</p>
</div><p><strong>nwagner@CareDx.com</strong></p>
<div class="lb-trans"><p><strong>nwagner@CareDx.com</strong></p>
</div><p><strong>Investors</strong></p>
<div class="lb-trans"><p><strong>投资者</strong></p>
</div><p>Caroline Corner</p>
<div class="lb-trans"><p>卡罗琳·科纳</p>
</div><p><strong>investor@CareDx.com</strong></p>
<div class="lb-trans"><p><strong>investor@CareDx.com</strong></p>
</div><p>Source: CareDx, Inc.</p>
<div class="lb-trans"><p>来源：CareDx, Inc.</p>
</div>

CareDx 公布 2025 年第四季度和全年财务业绩初步结果 | CDNA 股票新闻